01.02.2016
Formycon AG DE000A1EWVY8
DGAP-News: Formycon AG: Formycon appoints biotech expert Professor Johannes Buchner to the Advisory Board
DGAP-News: Formycon AG / Key word(s): Strategic Company Decision/Change of
Personnel
Formycon AG: Formycon appoints biotech expert Professor Johannes Buchner to
the Advisory Board
01.02.2016 / 08:00
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Press Release // February 1, 2016
Formycon appoints biotech expert Professor Johannes Buchner to the Advisory
Board
Munich - The biosimilars company Formycon is underpinning its claim to
scientific excellence by appointing Johannes Buchner, professor in
Biotechnology at the Technische Universität München (Technical University
of Munich) and President of the German Society for Biochemistry and
Molecular Biology (GBM), to its Advisory Board. Professor Buchner is a
globally recognized expert in biotechnological research and development.
After studying Biology and receiving his PhD from the University of
Regensburg in 1991, Buchner investigated new concepts in cancer treatment
during his postdoctoral stay at the National Institutes of Health in
Bethesda, USA. He returned to the University of Regensburg as a group
leader, and since 1998 he is a Professor for Biotechnology at the
Technische Universität München, Germany. His research focuses on chaperone
proteins and antibodies. Buchner is a member of the German Academy of
Sciences (Leopoldina) as well as the Bavarian Academy of Sciences and
Humanities. He has received numerous awards for his research, including the
Hans Neurath Award from the Protein Society and the Schleiden Medal awarded
by Leopoldina.
"I am delighted that we have been able to welcome Professor Johannes
Buchner, a highly renowned professional in the field of molecular biology
and antibody research. His expertise will play a significant role in our
Advisory Board and will support our development work", comments Dr. Carsten
Brockmeyer, CEO of Formycon AG.
In addition to Professor Buchner, the board consists of Dr. Gerhard
Schaefer und Dr. Bernhard Hampl, who are both highly experienced managers
and proven industry experts from the pharmaceutical sector.
About Formycon:
Formycon is a leading independent pure play developer of biosimilars and
has become a recognized innovator in this field. The company has extensive
experience in the development of complex biological molecules. Formycon's
specialist expertise allows the company to develop high-quality biosimilars
that meet the strict regulatory requirements of highly regulated markets
such as Europe and the United States. Formycon currently has three
biosimilars under development, with further product candidates already
identified. Two biosimilar candidates have been licensed out to Santo
Holding GmbH.
Contact:
Thorsten Schüller
Corporate Communications and Investor Relations
Formycon AG
Fraunhoferstr. 15
82152 Martinsried/Planegg/Germany
phone +49 (0) 89 - 86 46 67 150
fax + 49 (0) 89 - 86 46 67 110
[email protected] // www.formycon.com
Disclaimer:
This press release may contain forward-looking statements and information
which are based on our current expectations and certain assumptions.
Various known and unknown risks, uncertainties and other factors could lead
to material differences between the actual future results, financial
situation, performance of the company, development of the products and the
estimates given here.
Such known and unknown risks and uncertainties comprise, among others, the
research and development, the regulatory approval process, the timing of
the actions of regulatory bodies and other governmental authorities,
clinical results, changes in laws and regulations, product quality, patient
safety and patent litigation. With respect to pipeline products, Formycon
AG does not provide any representation, warranties or any other guarantees
that the products will receive the necessary regulatory approvals or that
they will prove to be commercially exploitable and/or successful.
Formycon AG assumes no obligation to update these forward-looking
statements or to correct them in case of developments which differ from
those anticipated.
This document neither constitutes an offer to sell nor a solicitation of an
offer to buy or subscribe for securities of Formycon AG. No public offering
of securities of Formycon AG will be made nor is a public offering
intended.
This document and the information contained therein may not be distributed
in or into the United States of America, Canada, Australia, Japan or any
other jurisdictions, in which such offer or such solicitation would be
prohibited. This document does not constitute an offer for the sale of
securities in the United States.
---------------------------------------------------------------------------
01.02.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Formycon AG
Fraunhoferstraße 15
82152 Planegg-Martinsried
Germany
Phone: 089 864667 100
Fax: 089 864667 110
Internet: www.formycon.com
ISIN: DE000A1EWVY8
WKN: A1EWVY
Listed: Regulated Unofficial Market in Berlin; Open Market (Entry
Standard) in Frankfurt
End of News DGAP News Service
---------------------------------------------------------------------------
433395 01.02.2016
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Formycon AG ISIN: DE000A1EWVY8 können Sie bei EQS abrufen
Biotechnologie , A1EWVY , FYB , XETR:FYB